The U.S. FDA is launching a program under which its commissioner can issue vouchers to companies he finds are aligned with ...

The biotech industry faces a mix of longstanding and novel political challenges amid President Donald Trump’s second term.

(Reuters) -The U.S. Food and Drug Administration on Tuesday announced that it will issue a new priority review voucher to ...

The US Food and Drug Administration announced a new national priority voucher plan that aims to cut drug review times to one ...

The FDA is launching a program to reward companies with accelerated drug review and speedy agency feedback, if their actions ...

The FDA is introducing a new priority voucher program designed to shorten the drug review process from 10 to 12 months down to one or two months, according to the agency. | The FDA is introducing a ...

Our investigation exposed a little-known practice inside the FDA that allowed more than 150 drugs or their ingredients into ...

Kraft Heinz will be pulling certain artificial dyes from its U.S. products starting in 2027 and will no longer roll out new ...

Garadacimab-gxii is the first and only treatment that targets factor XIIa (FXIIa) for the prophylactic prevention of reditary ...

Kraft Heinz announced on Tuesday that it will remove all FD&C artificial dyes from its U.S. portfolio by the end of 2027 amid ...

"Transparency is important to us at Wildtype." Wildtype is the third lab-grown meat producer to receive full government ...

Rein Therapeutics has paused patient enrollment and dosing in a mid-stage trial of its lung disease drug in the U.S. after ...